7th IPF Summit Revere Hotel Boston Common, Boston

With Nintedanib and Pirfenidone set to lose their patents in the next 3-6 years, Pliant Therapeutics moving into phase 2b, readouts expected from FibroGen’s phase 3 trial and Galecto’s phase 2 study and Bristol Myers Squibb’s and Boehringer Ingelheim’s clinical trials both well under way…the race is on to advance the next generation of IPF drugs and beat the benchmark set by the standard of care.

We’re at the precipice of hailing disease-modifying IPF drugs to patients with the increasing understanding of lung pathobiology and cell cross talk using multi-omic approaches expanding the horizons of therapeutic targets to slow, halt, reverse and regenerate progressively fibrosing lung tissue. Imaging and AI are being harnessed more than ever to show therapeutic efficacy beyond lung function and clinical trials are being designed to be more effective and swifter.

The 7th IPF Summit is the undisputed, comprehensive, end-to-end, 3-day conference for you and your team to grasp the latest readouts and take new insights back to your therapeutic development. Don’t miss this opportunity to discuss the latest unpublished data and network with 180+ movers and shakers in the pulmonary fibrosis field.

⌛ Event Dates & Venue

19 Sep - 21 Sep 2023, 9:00 am - 4:00 pm

💸 Website & Tickets

Go to Event Website
Ticket Pricing:
Drug Developer - Conference + Seminar Day: USD 4297.00, Drug Developer - Conference Only: USD 2999.00, Solution Provider - Conference + Seminar Day: USD 5297.00, Solution Provider - Conference Only: USD 3799.00, Academic Pricing - Conference + Seminar Day: USD 3697.00, Academic Pricing - Conference Only: USD 2599.00

◑ Topics | Categories